Axura

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

memantine hydrochloride

Available from:

Merz Pharmaceuticals GmbH

ATC code:

N06DX01

INN (International Name):

memantine

Therapeutic group:

Other anti-dementia drugs

Therapeutic area:

Alzheimer Disease

Therapeutic indications:

Treatment of patients with moderate to severe Alzheimer's disease.

Product summary:

Revision: 27

Authorization status:

Authorised

Authorization date:

2002-05-17

Patient Information leaflet

                                52
B. PACKAGE LEAFLET
53
PACKAGE LEAFLET: INFORMATION FOR THE USER
AXURA 10 MG FILM-COATED TABLETS
Memantine hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Axura is and what it is used for
2.
What you need to know before you take Axura
3.
How to take Axura
4.
Possible side effects
5.
How to store Axura
6.
Content of the pack and other information
1.
WHAT AXURA IS AND WHAT IT IS USED FOR
HOW DOES AXURA WORK
Axura contains the active substance memantine hydrochloride.
Axura belongs to a group of medicines known as anti-dementia
medicines.
Memory loss in Alzheimer’s disease is due to a disturbance of
message signals in the brain. The brain
contains so-called N-methyl-D-aspartate (NMDA)-receptors that are
involved in transmitting nerve
signals important in learning and memory. Axura belongs to a group of
medicines called NMDA-
receptor antagonists. Axura acts on these NMDA-receptors improving the
transmission of nerve
signals and the memory.
WHAT IS AXURA USED FOR
Axura is used for the treatment of patients with moderate to severe
Alzheimer’s disease.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AXURA
DO NOT TAKE AXURA
-
if you are allergic (hypersensitive) to memantine hydrochloride or any
of the other ingredients
of Axura tablets (listed in section 6).
WARNING AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Axura
-
if you have a history of epileptic seizures
-
if you have recently experienced a myocardial infarction (heart
attack), or if you are suffering
from conges
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Axura 10 mg film-coated tablets
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
Axura 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Axura 10 mg film-coated tablets
Each film-coated tablet contains 10 mg of memantine hydrochloride
equivalent to 8.31 mg memantine.
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
Each filmcoated tablet contains 5 mg of memantine hydrochloride
equivalent to 4.15 mg memantine.
Each film-coated tablet contains 10 mg of memantine hydrochloride
equivalent to 8.31 mg memantine.
Each film-coated tablet contains 15 mg of memantine hydrochloride
equivalent to 12.46 mg memantine.
Each film-coated tablet contains 20 mg of memantine hydrochloride
equivalent to 16.62 mg memantine.
Axura 20 mg film-coated tablets
Each film-coated tablet contains 20 mg of memantine hydrochloride
equivalent to 16.62 mg memantine.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Axura 10 mg film-coated tablets
Pale yellow to yellow, oval shaped film-coated tablet with breaking
line and engravings "1-0" on one
side and "M M" on the other side.
The tablet can be divided into equal doses.
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
The 5 mg film-coated tablets are white to off-white, oval-oblong
film-coated tablets with imprint ‘5’ on
one side and imprint ‘MEM’ on the other side.
The 10 mg film-coated tablets are pale yellow to yellow, oval shaped
film-coated tablet with breaking
line and engravings "1-0" on one side and "M M" on the other side. The
tablet can be divided into
equal doses.
The 15 mg film-coated tablets are orange to grey-orange, oval-oblong
film-coated tablets with imprint
‘15’ on one side and imprint ‘MEM’ on the other side.
The 20 mg film-coated tablets are pale red to grey-red, oval-oblong
film-coated tablets with imprint ‘20’
on one side and imprint ‘MEM’ on the other side.
Axura 20 mg film-coated tablets
Pale red to grey-red,
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-02-2024
Public Assessment Report Public Assessment Report Bulgarian 05-01-2012
Patient Information leaflet Patient Information leaflet Spanish 26-02-2024
Public Assessment Report Public Assessment Report Spanish 05-01-2012
Patient Information leaflet Patient Information leaflet Czech 26-02-2024
Public Assessment Report Public Assessment Report Czech 05-01-2012
Patient Information leaflet Patient Information leaflet Danish 26-02-2024
Public Assessment Report Public Assessment Report Danish 05-01-2012
Patient Information leaflet Patient Information leaflet German 26-02-2024
Public Assessment Report Public Assessment Report German 05-01-2012
Patient Information leaflet Patient Information leaflet Estonian 26-02-2024
Public Assessment Report Public Assessment Report Estonian 05-01-2012
Patient Information leaflet Patient Information leaflet Greek 26-02-2024
Public Assessment Report Public Assessment Report Greek 05-01-2012
Patient Information leaflet Patient Information leaflet French 26-02-2024
Public Assessment Report Public Assessment Report French 05-01-2012
Patient Information leaflet Patient Information leaflet Italian 26-02-2024
Public Assessment Report Public Assessment Report Italian 05-01-2012
Patient Information leaflet Patient Information leaflet Latvian 26-02-2024
Public Assessment Report Public Assessment Report Latvian 05-01-2012
Patient Information leaflet Patient Information leaflet Lithuanian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-02-2024
Public Assessment Report Public Assessment Report Lithuanian 05-01-2012
Patient Information leaflet Patient Information leaflet Hungarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 26-02-2024
Public Assessment Report Public Assessment Report Hungarian 05-01-2012
Patient Information leaflet Patient Information leaflet Maltese 26-02-2024
Public Assessment Report Public Assessment Report Maltese 05-01-2012
Patient Information leaflet Patient Information leaflet Dutch 26-02-2024
Public Assessment Report Public Assessment Report Dutch 05-01-2012
Patient Information leaflet Patient Information leaflet Polish 26-02-2024
Public Assessment Report Public Assessment Report Polish 05-01-2012
Patient Information leaflet Patient Information leaflet Portuguese 26-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 26-02-2024
Public Assessment Report Public Assessment Report Portuguese 05-01-2012
Patient Information leaflet Patient Information leaflet Romanian 26-02-2024
Public Assessment Report Public Assessment Report Romanian 05-01-2012
Patient Information leaflet Patient Information leaflet Slovak 26-02-2024
Public Assessment Report Public Assessment Report Slovak 05-01-2012
Patient Information leaflet Patient Information leaflet Slovenian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 26-02-2024
Public Assessment Report Public Assessment Report Slovenian 05-01-2012
Patient Information leaflet Patient Information leaflet Finnish 26-02-2024
Public Assessment Report Public Assessment Report Finnish 05-01-2012
Patient Information leaflet Patient Information leaflet Swedish 26-02-2024
Public Assessment Report Public Assessment Report Swedish 05-01-2012
Patient Information leaflet Patient Information leaflet Norwegian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 26-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 26-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 26-02-2024
Patient Information leaflet Patient Information leaflet Croatian 26-02-2024

Search alerts related to this product

View documents history